Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 2
1993 1
1994 2
1995 1
1996 4
1997 3
1998 3
1999 1
2000 3
2001 4
2002 4
2003 9
2004 8
2005 5
2006 4
2007 5
2008 3
2009 5
2010 17
2011 9
2012 12
2013 14
2014 12
2015 12
2016 14
2017 14
2018 5
2019 13
2020 10
2021 10
Text availability
Article attribute
Article type
Publication date

Search Results

184 results
Results by year
Filters applied: . Clear all
Page 1
Interrogating open issues in cancer precision medicine with patient-derived xenografts.
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Byrne AT, et al. Among authors: maelandsmo gm. Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Nat Rev Cancer. 2017. PMID: 28104906 Free article. Review.
Patient-derived xenograft models: an emerging platform for translational cancer research.
Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A. Hidalgo M, et al. Among authors: maelandsmo gm. Cancer Discov. 2014 Sep;4(9):998-1013. doi: 10.1158/2159-8290.CD-14-0001. Epub 2014 Jul 15. Cancer Discov. 2014. PMID: 25185190 Free PMC article. Review.
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM. Dillard P, et al. Among authors: maelandsmo gm. Mol Ther. 2021 Mar 3;29(3):1199-1213. doi: 10.1016/j.ymthe.2020.11.019. Epub 2020 Nov 17. Mol Ther. 2021. PMID: 33212301 Free article.
Soluble AXL as a marker of disease progression and survival in melanoma.
Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, Flørenes VA, Mælandsmo GM. Flem-Karlsen K, et al. Among authors: maelandsmo gm. PLoS One. 2020 Jan 9;15(1):e0227187. doi: 10.1371/journal.pone.0227187. eCollection 2020. PLoS One. 2020. PMID: 31917795 Free PMC article.
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy.
Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM. Pandya AD, et al. Among authors: maelandsmo gm. Int J Nanomedicine. 2019 Aug 6;14:6269-6285. doi: 10.2147/IJN.S208938. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31496685 Free PMC article.
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma.
Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T. Nyakas M, et al. Among authors: maelandsmo gm. Clin Exp Immunol. 2019 Jul;197(1):74-82. doi: 10.1111/cei.13283. Epub 2019 Mar 21. Clin Exp Immunol. 2019. PMID: 30821848 Free PMC article. Clinical Trial.
184 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page